The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Abatacept has been granted breakthrough therapy designation by the U.S. Food & Drug Administration (FDA) for the prevention of acute graft-versus-host disease (GvHD) in patients who have had hematopoietic stem cell transplantation (HSCT) from unrelated donors.1
Acute GvHD is a potentially life-threatening complication affecting up to 40% of patients who undergo HSCT from unrelated donors, there are currently no approved preventative therapies. Abatacept blocks donor T-cell activation by binding to and inhibiting proteins that are involved in co-stimulation, which results in stopping donor T cells from attacking the recipient’s healthy cells.2
Breakthrough therapy designation was based on a phase II trial assessing abatacept plus standard GvHD prophylaxis in patients with hematologic malignancies treated with HSCT from unrelated donors. Leslie Kean, lead study investigator and the director of the stem cell transplantation program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, US said “A therapy that lowers the risk [for] GvHD in unrelated stem cell transplants would potentially allow more patients to receive a transplant, which typically is the last option to treat hematologic cancers, after other therapies have been used unsuccessfully.” 1
Abatacept is currently approved in the US for the treatment of certain arthritic conditions in both adults and children. 1
References